In the January 2009 issue, in the Review by Deal, the randomized controlled trial evaluating four doses of odanacatib was described incorrectly on page 22. In this trial odanacatib was given weekly, not daily.
There was also an error in the corresponding author's email address. The correct address is dealc@ccf.org.
Additional information
The online version of the original article can be found at 10.1038/ncprheum0977
Rights and permissions
About this article
Cite this article
Deal, C. Erratum: Potential new drug targets for osteoporosis. Nat Rev Rheumatol 5, 174 (2009). https://doi.org/10.1038/ncprheum1027
Issue Date:
DOI: https://doi.org/10.1038/ncprheum1027
